Common stock
- Symbol
- VALU
- Exchange
- NASDAQ
- Classification
- COMMON
- Status
- Current
Current Report · Items 5.02 · 8-K
Value Line, Inc.
VALUNASDAQEQUITYCurrent
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements
Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Mr. Alfred R. Fiore, a director of the Company since 2010, died on December 6, 2025. On January 16, 2026, Dr. Alexander J. Swistel was appointed by the Board of Directors of Value Line, Inc.…
Registered securities in this filing
Value Line, Inc. · 8-K · Filed 2026-01-16
Disclosure sections
Item 5.02Item 5.02 - Departure/Election of Directors
Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
Mr. Alfred R. Fiore, a director of the Company since 2010, died on December 6, 2025.
On January 16, 2026, Dr. Alexander J. Swistel was appointed by the Board of Directors of Value Line, Inc. (the “Company”) to serve as director of the Company and as a member of the Board’s Audit Committee. Dr. Swistel is retired Associate Professor at Weill Cornell Medical College and is a graduate of Harvard University and Brown University School of Medicine. There is no arrangement or understanding between Dr. Swistel and any other person pursuant to which Dr. Swistel was selected as a director of the Company. No family relationships exist between Dr. Swistel and any of the Company’s directors or executive officers. There are no transactions to which the Company was or is a participant and in which Dr. Swistel has a material interest subject to disclosure under Item 404(a) of Regulation S-K. Dr. Swistel will receive the same compensation as other members of the Audit Committee, which is a director’s fee of $40,000 per year.